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tenolol Is Dead:
ong Live Beta-Blockade
angalore et al. (1) recently reported that a lower heart rate was
ssociated with a greater risk for all-cause mortality (r  0.51;
 0.0001), cardiovascular mortality (r  0.61; p  0.0001),
yocardial infarction (MI) (r  0.85; p  0.0001), stroke
r  0.20; p  0.06), or heart failure (r  0.64; p  0.0001).
hey concluded that beta-blocker–associated reduction in heart
ate increased the risk of cardiovascular events and death in
ypertensive patients, in contrast to patients with MI and heart
ailure. In an accompanying editorial, Kaplan (2) stated that
eta-blockers will continue to be indicated for heart failure,
achyarrhythmias, and secondary prevention post-MI, but not
or treatment of hypertension in patients without these com-
elling indications. However, as the authors wrote, care should
e taken in extrapolating these findings to newer beta-blockers,
specially the vasodilating agents (e.g., nebivolol and carvedilol)
3). It should be emphasized that the studies included in this
eview used atenolol almost exclusively: 78% of patients received
tenolol; 12%, atenolol/metoprolol/pindolol or hydrochlorothi-
zide; 9%, oxprenolol; and 1%, propranolol. Thus, it is difficult
o extrapolate the findings to newer vasodilating beta-blockers.
uture studies should strive to determine whether atenolol per
e or the reduction of heart rate is responsible for increased
ardiovascular risk. This issue needs to be resolved, because the
ndings would have major clinical implications (3).
Another important issue to resolve is the effect of drugs on
entral pressure. The benefits of heart rate reduction may be
egated by a drug that lowers heart rate while simultaneously
ncreasing central pressure (4). Different drugs, especially beta-
lockers, have differential effects on peripheral and central pres-
ure, and a number of studies have now shown that central pressure
s a better predictor of outcome than pressure in the arm (5,6). As
emonstrated in the CAFE (Conduit Artery Function Evaluation)
tudy, antihypertensive medications can have substantially different
ffects on central aortic pressure and hemodynamics, despite a
imilar impact on brachial blood pressure (7). Vasodilatory beta-
lockers may well offset any deleterious hemodynamic effects of
eart rate reduction by decreasing wave reflection from the
eriphery. In a study by Dhakam et al. (8), the central hemody-
amic effects of nebivolol and atenolol were compared in patients
ith systolic hypertension. Despite similar reductions in peripheral
lood pressure, nebivolol reduced central pulse pressure more than
tenolol. Both drugs reduced aortic stiffness, but nebivolol had less
mpact on the aortic augmentation index. These findings suggest hhat important differences may exist among drugs in the beta-
locker class.
Finally, beta-blockade remains very important in the treatment
f cardiovascular disease, and in hypertensive patients with coex-
sting angina. Further, hypertensive patients younger than 50 years
ld may benefit more from beta-blockade than older patients, as
hey have a different hemodynamic form of hypertension (9).
owever, all evidence to date (4) suggests that a beta-blocker other
han atenolol should be chosen when beta-blockade is required.
It is premature to sound the death knell for all beta-blockers in
he treatment of hypertension based upon the Bangalore et al. (1)
eview, but it is high time to stop prescribing atenolol.
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eta-Blockers, Hypertension, and
andomized Controlled Trials:
cience and Sensibility
angalore et al. (1) suggest that beta-blocker–induced reduction of
eart rate increases the risk for cardiovascular events and death for
